Nabi-HB Decision Anticipated “Shortly” Following FDA Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Blood Products Advisory Committee recommended approval of Nabi’s BLA for the treatment of liver transplant patients.